[Effect of intranasal treatment with XXXX on polyp recurrence after polypectomy and ethmoidectomy].

@entity1 @entity2708 @entity2951 @entity5254 @entity480 @entity1068
OBJECTIVE: To evaluate the influence of polypectomy and anterior ethmoidectomy associated with intranasal applications of @entity2951 on the recurrence of @entity480 . METHOD: Fifty one @entity1 (19 females, 32 males, mean age 43) undergoing polypectomy and anterior ethmoidectomy were included in the study. In 29 @entity1 , a @entity2708 pellet soaked with @entity2951 (3 x 10(-6) mol, dissolved in 70% @entity1068 ) was left into the middle meatus for 20 min under local anaesthesia. As a control group, 22 @entity1 were treated with the @entity2951 vehicle alone (70% @entity1068 ). All @entity1 studied received the intranasal @entity2951 or vehicle treatment once a week for 5 weeks. The clinical objective examination and the subjective evaluation of nasal obstruction, @entity5254 were recorded by means of a visual analogic scale graded from 0 to 4 throughout the study. RESULT: @entity1 treated with intranasal @entity2951 application reported 9 months later and 55 months later separately, a marked reduction of their subjective evaluation of nasal obstruction when compared to the pretreatment evaluation (P < 0.01). In contrast, @entity1 treated with the @entity2951 vehicle alone did not have any significant improvement of their subjective evaluation of nasal obstruction. Subjective @entity5254 was not modified by either treatment. Of 29 @entity1 with @entity2951 treatment, 25 (86.2%) @entity1 (9 months later) and 20 (69%) @entity1 (55 months later) showed satisfactory result, compared to 10 (45.4%) @entity1 and 8 (36.4%) @entity1 separately in the control group, the difference was significant (P < 0.01). CONCLUSION: Intranasal @entity2951 application can reduce polyp recurrence and nasal obstruction after polypectomy and ethmoidectomy.
